Analysts Issue Forecasts for ESPR FY2026 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Esperion Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will earn $0.02 per share for the year. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Several other analysts have also recently weighed in on ESPR. The Goldman Sachs Group dropped their price objective on Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Thursday, April 17th. Needham & Company LLC decreased their target price on Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Friday, April 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.25.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR opened at $1.21 on Wednesday. The stock has a market cap of $239.82 million, a PE ratio of -1.89 and a beta of 0.67. The business has a fifty day moving average of $0.95 and a two-hundred day moving average of $1.68. Esperion Therapeutics has a 52-week low of $0.69 and a 52-week high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). The firm had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. J.W. Cole Advisors Inc. acquired a new position in Esperion Therapeutics during the 4th quarter worth approximately $66,000. Sigma Planning Corp grew its holdings in Esperion Therapeutics by 1,455.8% in the 4th quarter. Sigma Planning Corp now owns 190,441 shares of the biopharmaceutical company’s stock valued at $419,000 after buying an additional 178,200 shares in the last quarter. Summit Wealth Group LLC grew its holdings in Esperion Therapeutics by 292.5% in the 4th quarter. Summit Wealth Group LLC now owns 157,000 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 117,000 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Esperion Therapeutics by 602.8% in the 4th quarter. Victory Capital Management Inc. now owns 173,083 shares of the biopharmaceutical company’s stock valued at $381,000 after buying an additional 148,456 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Esperion Therapeutics during the 4th quarter worth $98,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.